Dermatologic Care of the Transplant Patient
September 2010
in “
Journal of the Dermatology Nurses’ Association
”
New to Rapamycin? There is a guide in the encyclopedia. Read the guide → 
Studysummary This article provides a detailed analysis of immunosuppressive medications in transplant patients and discusses the increased risk of skin cancer, but it reports no new experimental results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The 2010 document analyzed the impact of immunosuppressive medications on the risk of nonmelanoma skin cancer (NMSC) in transplant patients, noting an increased risk with prolonged immunosuppression. It was found that the incidence of NMSC, particularly aggressive squamous cell carcinomas (SCCs), increases with the duration and intensity of immunosuppression. The document reviewed various immunosuppressive medications and their side effects on skin health, including the development of cutaneous malignancies. Management strategies for skin cancer in transplant patients were outlined, emphasizing early and aggressive treatment, and the use of topical and systemic agents. A study involving 1671 renal transplant recipients indicated that Sirolimus-based therapy could lower malignancy rates, but mTOR inhibitors, while having antitumoral properties, often led to cutaneous adverse events. The document concluded with the challenge of balancing immunosuppression with skin cancer risk and mentioned ongoing clinical trials to explore management strategies.
